复合库申注射通过调节MTSS1/ARPC3/F-actin来抑制乳腺癌肺转移
Yu-Tong Wang1, Quan-Yang Liao1, Yun-Zhu Dong2
1College of Traditional Chinese Medicine, Yunnan University of Chinese Medicine, Kunming, 650500, China.
Journal of ethnopharmacology
|May 30, 2025
概括
复合Kushen注射 (CKI) 和其成分母蛋白抑制乳腺癌的生长和肺转移. 它们通过调节MTSS1/ARPC3/F-actin通路而起作用,并抑制上皮质-介质细胞过渡 (EMT).
科学领域:
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
- 传统中国医药 传统中国医药
背景情况:
- 复合库申注射 (CKI) 是一种用于恶性瘤的传统中医药.
- 马特林是CKI的关键成分,显示出抗癌性质.
- 对于CKI对乳腺癌肺转移的作用机制尚未完全理解.
研究的目的:
- 为了研究CCI对乳腺癌肺转移的影响.
- 阐明CCI作用的潜在分子机制.
主要方法:
- 在实验室测试 (CCK-8,亡,迁移,入侵) 和在4T1瘤携带小鼠的体内研究.
- 蛋白质组分析,西式涂抹,免疫组织化学和免疫光学,以评估蛋白质表达和细胞变化.
- LC-MS用于识别化学成分并评估matrine的特定影响.
主要成果:
- CKI抑制了乳腺癌细胞的活力,增殖,迁移和入侵,同时诱导了亡.
- 在体内,CKI抑制了瘤生长和肺转移,没有显著的器官毒性.
- CKI调节了MTSS1,ARPC3,E-cadherin,N-cadherin和vimentin的表达,抑制了上皮细胞-介质细胞过渡 (EMT) 并改变了F-actin的结构.
结论:
- CKI和matrine有效地抑制了乳腺癌的进展和肺转移.
- 该机制涉及调节MTSS1/ARPC3/F-actin通路并抑制EMT.
- CKI和matrine在乳腺癌治疗中显示出显著的治疗潜力.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
17.9K
13:18Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma
Published on: March 3, 2023
1.2K
相关概念视频
Drugs that Stabilize Microtubules
2.0K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.0K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
Drugs that Destabilize Microtubules
1.9K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
1.9K
